WallStSmart

Alarum Technologies Ltd. (ALAR)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 535% more annual revenue ($258.90M vs $40.76M). ALAR leads profitability with a 2.4% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

ALAR

Hold

38

out of 100

Grade: F

Growth: 7.3Profit: 4.0Value: 5.7Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALARUndervalued (+76.2%)

Margin of Safety

+76.2%

Fair Value

$29.41

Current Price

$6.65

$22.76 discount

UndervaluedFair: $29.41Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALAR2 strengths · Avg: 10.0/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
60.4%10/10

Revenue surging 60.4% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

ALAR4 concerns · Avg: 3.0/10
Market CapQuality
$48.52M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.3%3/10

ROE of 3.3% — below average capital efficiency

Profit MarginProfitability
2.4%3/10

2.4% margin — thin

Operating MarginProfitability
0.3%3/10

Operating margin of 0.3%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ALAR

The strongest argument for ALAR centers on Price/Book, Revenue Growth. Revenue growth of 60.4% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : ALAR

The primary concerns for ALAR are Market Cap, Return on Equity, Profit Margin. A P/E of 66.1x leaves little room for execution misses. Thin 2.4% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ALAR is growing revenue faster at 60.4% — sustainability is the question.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 38/100) and 43.0% revenue growth. ALAR offers better value entry with a 76.2% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alarum Technologies Ltd.

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Alarum Technologies Ltd. provides cybersecurity and privacy solutions to consumers and enterprises in Israel, the United States, Hong Kong, the Asia Pacific, and internationally. The company is headquartered in Tel Aviv-Yafo, Israel.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?